Goldman Sachs Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: IOVA) | Delayed: 8.73 -0.1 (1.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.83 | 52 Week High | $ | |||
| Open | $8.87 | 52 Week Low | $ | |||
| Day High | $9.10 | P/E | N/A | |||
| Day Low | $8.47 | EPS | $ | |||
| Volume | 14,376,303 | |||||
